Ultrastructural and pathogenicity of Brevibacillus laterosporus against sinantropic muscoid dipterans

Author(s):  
Lorrane Andrade Pereira ◽  
Margareth Maria Carvalho Queiroz ◽  
Suzana Côrte‐Real Faria ◽  
Viviane Zahner
2003 ◽  
Author(s):  
Charles Thomas Parker ◽  
Nicole Danielle Osier ◽  
George M Garrity

2016 ◽  
Vol 121 (4) ◽  
pp. 442-449 ◽  
Author(s):  
Mayur B. Kurade ◽  
Tatoba R. Waghmode ◽  
Rahul V. Khandare ◽  
Byong-Hun Jeon ◽  
Sanjay P. Govindwar

Antibiotics ◽  
2018 ◽  
Vol 7 (4) ◽  
pp. 105 ◽  
Author(s):  
T. Brady ◽  
Christopher Fajardo ◽  
Bryan Merrill ◽  
Jared Hilton ◽  
Kiel Graves ◽  
...  

Brevibacillus laterosporus is often present in beehives, including presence in hives infected with the causative agent of American Foulbrood (AFB), Paenibacillus larvae. In this work, 12 B. laterosporus bacteriophages induced bactericidal products in their host. Results demonstrate that P. larvae is susceptible to antimicrobials induced from field isolates of the bystander, B. laterosporus. Bystander antimicrobial activity was specific against the pathogen and not other bacterial species, indicating that the production was likely due to natural competition between the two bacteria. Three B. laterosporus phages were combined in a cocktail to treat AFB. Healthy hives treated with B. laterosporus phages experienced no difference in brood generation compared to control hives over 8 weeks. Phage presence in bee larvae after treatment rose to 60.8 ± 3.6% and dropped to 0 ± 0.8% after 72 h. In infected hives the recovery rate was 75% when treated, however AFB spores were not susceptible to the antimicrobials as evidenced by recurrence of AFB. We posit that the effectiveness of this treatment is due to the production of the bactericidal products of B. laterosporus when infected with phages resulting in bystander-killing of P. larvae. Bystander phage therapy may provide a new avenue for antibacterial production and treatment of disease.


2011 ◽  
Vol 5 (18) ◽  
pp. 2675-2681 ◽  
Author(s):  
Song Zhen ◽  
Liu Kaiqi ◽  
Lu Changxu ◽  
Yu Jian ◽  
Ju Ruicheng ◽  
...  

2018 ◽  
Vol 13 (2) ◽  
pp. 95 ◽  
Author(s):  
Nurbaya Nurbaya ◽  
Muharijadi Atmomarsono

To counter disease problems caused by vibriosis in shrimp hatchery, this recent study used three different probiotics to be tested on tiger shrimp (Penaeus monodon) postlarvae. The study arranged four treatments as follows: A: a combination of three liquid-form probiotics Brevibacillus laterosporus BT951, Bacillus subtilis BM12, and B. licheniformis BM58; B: a combination of three powder-form probiotics Brevibacillus laterosporus BT951, Bacillus subtilis BM12, and B. licheniformis BM58; C: a commercial powder probiotic containing Bacillus subtilis; and D: control (without probiotic), each treatment with three replications. This study was set up in a completely randomized design experiment using twelve fiberglass tanks filled with 750 L sterile sea water and stocked with 30,000 nauplii in the Awarange shrimp hatchery of the Research Institute for Brackishwater Aquaculture and Fisheries Extension Installation in Barru. Variables observed in this study were the survival rate of the shrimp postlarvae at the end of the experiment, total vibrio count (TBV) and total plate count of common bacteria (TPC) in the culture water. The results showed that the survival rate of tiger shrimp applied either in liquid (A: 61.5±4.7%) or powder form (B: 48.6±6.8%), and control (without probiotic) (D: 51.2±4.4%) were not significantly different (P>0.05). However, survival rates in these three treatments differed (P<0.05) with that of the commercial probiotic (C: 21.7±9.9%). TBV/TPC ratio in the tank waters treated with the commercial probiotic (2.26-37.52%) was much higher than that of the liquid form probiotic (0.86-1.98%), powder form probiotic (1.25-8.37%), and control (1.93-2.84%). Ammonia-nitrogen in treatment C (1.462-2.989 mg/L) was relatively higher than that of in treatment A (1.595-2.435 mg/L), treatment B (1.644-2.115 mg/L), and treatment D (1.051-1.858 mg/L).


Sign in / Sign up

Export Citation Format

Share Document